Trial Profile
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 13 Dec 2022 Results assessing benefits of a second Allo-HSCT after CAR-T Cell therapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
- 08 Dec 2020 Results of pooled analysis of a data pooled from NCT03173417; NCT02546739; and ChiCTR-ONC-17012829 studies assessing the feasibility and efficacy in 37 patients with refractory/relapsed (R/R) B-ALL who received CAR T-cells derived from related donors, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology